Pharma: Page 69
-
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
J&J picks top coronavirus vaccine candidate; human tests to start in September
Together with BARDA, the pharma has agreed to spend $1 billion co-funding vaccine research, development and testing.
By Jacob Bell • March 30, 2020 -
Sanofi adds mRNA to coronavirus vaccine push
A deal with Translate Bio to develop an mRNA-based vaccine adds the newer technology to the French pharma’s pandemic response.
By Jonathan Gardner • March 27, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Bristol Myers investors breathe easier as multiple sclerosis drug approved by FDA
Regulatory clearance for Zeposia is the first of three drug approval milestones that must be met for former Celgene shareholders to see the full value of the 2019 acquisition.
By Jonathan Gardner • March 26, 2020 -
In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug
After sparking controversy, the biotech asked the FDA to rescind a designation designed to encourage research into therapies for rare diseases.
By Jonathan Gardner • March 25, 2020 -
AstraZeneca turns again to UK's Silence in renewed RNAi push
AstraZeneca and Silence Therapeutics, which first partnered in 2007, will team up to develop RNA interference drug candidates for diseases of the liver, heart, kidney and lung.
By Ned Pagliarulo • Updated March 25, 2020 -
Shutterstock: LightField Studios
Sponsored by ZSCOVID-19 and pharma's in-person sales model
Once the pharma industry and its customers learn to function in a world without face-to-face detailing, we may see the digital flip switch with physicians preferring to engage via digital channels.
By Pratap Khedkar Co-author: Daniel Brox • March 24, 2020 -
Permission granted by Roche
Leukemia drug from Roche, AbbVie extends survival, study finds
Paired with chemotherapy, Venclexta succeeded in a Phase 3 acute myeloid leukemia trial just weeks after falling short in another combination study.
By Jonathan Gardner • March 23, 2020 -
Courtesy of Eli Lilly
Lilly, Galapagos halt trials as coronavirus deepens impact on drug research
The moves likely herald similar announcements by other large drugmakers as medical centers focus resources on treating patients with COVID-19.
By Ben Fidler • Updated March 23, 2020 -
Permission granted by Stein IAS
Sponsored by CovanceAddressing the challenges of data management for pharmaceutical and biotechnology companies
The need for timely availability of clean data based on unique sponsor format/industry requirements has become extremely complex.
March 18, 2020 -
CDC/Alissa Eckert, MS. "covid-19 coronavirus on black background". Retrieved from https://www.cdc.gov/media/subtopic/images.htm.
No White House offer for coronavirus vaccine access, CureVac says
An abrupt exit by CEO Daniel Menichella following a meeting with President Donald Trump, and the medical leave taken this week by his successor, were "pure coincidence," a board member said.
By Jonathan Gardner • March 17, 2020 -
Pharma salesforces brought to a halt as coronavirus shutters economy
Coronavirus' spread, and the measures taken by states and cities to contain it, are forcing drugmakers like Amarin, Pfizer and Merck & Co. to pull back their sales teams from hospitals and doctors' offices.
By Ned Pagliarulo • March 17, 2020 -
Permission granted by University of Pennsylvania
Deep DiveBig pharma shied away from gene therapy for years. Academia picked up the slack
The byproduct was richer licensing fees for universities and a throng of startups, but also questions on fair prices and research priorities.
By Jonathan Gardner • March 17, 2020 -
Courtesy of Regeneron Pharmaceuticals
Regeneron and Sanofi speed Kevzara into coronavirus trials
Positive signs from a Chinese test of Roche's Actemra support the companies' decision to start studying their anti-inflammatory drug against COVID-19.
By Jonathan Gardner • March 16, 2020 -
Courtesy of Eli Lilly
With AbCellera deal, Lilly becomes latest pharma to start coronavirus program
Lilly hopes to begin human testing of a therapeutic antibody within four months, the company's top scientist said.
By Ned Pagliarulo • March 13, 2020 -
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
Results from a Phase 3 combination study in the tumor type read out negative, marking a rare miss for the pharmas' fast-growing cancer drug.
By Jonathan Gardner • March 12, 2020 -
Shutterstock: digitally enhanced by ZS.
Sponsored by ZSThe future of data in pharma
The world is becoming more and more data dependent while slow, tectonic shifts are under way across healthcare.
March 11, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Coronavirus spread prompts FDA to postpone nearly all overseas inspections
The agency's decision was based on U.S. government travel restrictions, but it said "alternative tools and methods" will help it maintain oversight.
By Jonathan Gardner • March 10, 2020 -
Acceleron shelves drug after disappointing readout
Despite hitting the main goal of a mid-stage neuromuscular study, Acceleron isn't convinced its drug offers meaningful improvement to muscle function or quality of life.
By Jacob Bell • March 10, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
Tracking biopharma's response to the new coronavirus
The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.
By Jacob Bell • Updated July 7, 2020 -
Courtesy of Eli Lilly
As US coronavirus cases mount, top drugmakers tell employees to work from home
Eli Lilly and Takeda are asking thousands of their U.S.-based employees to practice "social distancing," while Biogen tries to contain an outbreak among staff who attended a Boston meeting earlier this month.
By Ned Pagliarulo • March 9, 2020 -
Jacob Bell/BioPharma Dive
AstraZeneca immunotherapy combination falls short in bladder cancer trial
Results from a Phase 3 bladder cancer study combining two checkpoint inhibitors failed to show a survival benefit, raising questions about other trials.
By Jonathan Gardner • March 6, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Takeda starts work on treatment for coronavirus illness
The plan is to take blood proteins of patients recovering from the novel virus and turn them into an immune-boosting therapy that mitigates or prevents illness in others.
By Jacob Bell • March 4, 2020 -
Federal prosecutors make another claim against Mallinckrodt over Acthar prices
A quirk in the FDA approval for the multi-use drug allowed first Questcor and then Mallinckrodt to understate rebates owed to Medicaid, the lawsuit claims.
By Jonathan Gardner • March 4, 2020 -
High prices fuel pharma profits. New research provides more context
Drugmakers often enjoy significantly wider net income margins than large companies in other industries, and those profits have come amid steady list — and net — price hikes for hundreds of medicines.
By Ned Pagliarulo • March 3, 2020 -
New estimate puts cost to develop a new drug at $1B, adding to long-running debate
Pharma companies spend $300 million to $400 million bringing a new medicine to market, but per-product R&D costs are much higher after accounting for the many drugs that fail in testing.
By Jonathan Gardner • March 3, 2020
Previous
